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MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that can play critical
roles as regulators of numerous pathways and biological processes including the immune
response. Emerging as one of the most important miRNAs to orchestrate immune and
inflammatory signaling, often through its recognized target genes, IRAK1 and TRAF6, is
microRNA-146a (miR-146a). MiR-146a is one, of a small number of miRNAs, whose expres-
sion is strongly induced following challenge of cells with bacterial endotoxin, and prolonged
expression has been linked to immune tolerance, implying that it acts as a fine-tuning
mechanism to prevent an overstimulation of the inflammatory response. In other cells,
miR-146a has been shown to play a role in the control of the differentiation of megakary-
ocytic and monocytic lineages, adaptive immunity, and cancer. In this review, we discuss
the central role prescribed to miR-146a in innate immunity. We particularly focus on the
role played by miR-146a in the regulation and signaling mediated by one of the main pattern
recognition receptors, toll/IL-1 receptors (TLRs). Additionally, we also discuss the role of
miR-146a in several classes of autoimmune pathologies where this miRNA has been shown
to be dysregulated, as well as its potential role in the pathobiology of neurodegenerative
diseases.
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INTRODUCTION
Innate immunity is the critical first line of defense against invading
microbial pathogens, and is the primary effector of the inflam-
matory response and initiator of the adaptive immune response.
Microbial pathogens are recognized by several families of pat-
tern recognition receptors (PRRs) that interact with conserved
molecular structures that are broadly conserved on most microor-
ganisms, which are known as pathogen associated molecular pat-
terns (PAMPs) or danger associated molecular patterns (DAMPs)
(1). These interactions trigger a cascade of intra-cellular signaling
that results in the induction of transcription of pro-inflammatory
cytokines and interferons (IFNs).
The best characterized PRRs in regards to their microbial lig-
ands, downstream signaling, and the effectors that are induced
are undoubtedly members of the toll receptor family (2). Other
families include the retinoic acid-inducible gene I (RIG-I)-like
receptors and Nod-like receptors. Downstream signaling follow-
ing stimulation of these receptors is intricately regulated by a huge
variety of extra-cellular and intra-cellular mechanisms involving
kinases, phosphatases, transcriptional co-activators, membrane
proteins, and trafficking molecules, among others. Recently, a
novel post-transcriptional mechanism mediated by small RNA
species known as microRNAs (miRNAs) has been added to the
list of important regulators of PRR signaling (Figure 1).
MiRNAs were first identified in 1993 by the laboratory of Victor
Ambros (3). They found that a 22 nucleotide long RNA, tran-
scribed from the lin-4 gene, could bind to the 3′ untranslated
region (UTR) of the lin-14 messenger RNA (mRNA) of C. ele-
gans through Watson and Crick complementary base-pairing and
thereby inhibit the translation of the mRNA into a functional
protein. At first thought to be an idiosyncrasy of this particular
species, miRNAs were soon discovered to be present in a wide
assortment of vertebrate species and cell types and it has become
evident that these molecules exhibit important functions in the
post-transcriptional regulation of protein synthesis (4).
Mature miRNAs are transcribed as pre-cursor transcripts either
as independently or polycistronic clusters, or as introns of coding
genes (5, 6). Their expression is generally highly regulated in tissue-
and development-specific expression patterns, implying an impor-
tant contribution to cell-type specific protein expression profiles.
Due to their mode of function, miRNAs are especially well suited
to be part of auto-regulatory feed-back loops. In particular cases,
they are able to directly target their own regulators, thereby being
able to “fine-tune” their own expression (7, 8). MiRNAs interact
with their target genes by binding to complementary sequences in
the 3′UTR of the target mRNA(s), see Figure 1. Most important
for efficient binding is the continuous base-pairing of the “seed-
region,” which is represented by miRNA nucleotides 2→ 8 in the
5′ region (9). In most animals, however, the overall base-pairing is
imperfect leading to inhibited protein synthesis that is mediated
by either translational repression and/or a promoting effect on
mRNA deadenylation and decay.
The discovery of hundreds of experimentally verified miR-
NAs in mammals (http://www.mirbase.org/) has highlighted the
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FIGURE 1 | IRAK1 andTRAF6 are molecular targets of miR-146a. After the
primary transcript of miRNA-146a is generated by RNA polymerase, the
primary miRNA is processed by Drosha in the nucleus to produce a short
hairpin pre-cursor miRNA (pre-miRNA) transcript, which is then shuttled into
the cytoplasm. Further processing in the cytoplasm by Dicer produces the
final mature 22-basepair dsRNA. This mature miRNA complex is then
incorporated into the RNA-induced silencing complex in the cytoplasm. The
seed-sequence binds to complimentary sequences in the 3′untranslated
region (UTR) of its target mRNA transcripts, such as IRAK1, and TRAF6. This
results in translational repression of IRAK1 and TRAF6.
importance of miRNA-dependent mechanisms as pervasive reg-
ulators of the genome. Since on average each miRNA is able to
repress hundreds of target mRNAs (10,11), computational analysis
predicts that as much as 30–60% of mammalian genes may be con-
trolled by these molecules (12). By targeting a plethora of mRNAs,
miRNAs can regulate multiple pathways and biological processes
simultaneously. Nevertheless, many miRNAs have now been found
to not only participate in these large-scale processes but also to
“fine-tune”the accurate levels of their target genes in a wide assort-
ment of cells and tissues (13, 14). The first indication that miRNAs
may play a role in the immune response originated from work that
showed the selective expression of several miRNAs in cells of the
immune system (15). Since then, numerous studies have revealed
important physiological roles for miRNAs in the regulation of both
the innate and adaptive immune response. In particular miR-146
and miR-155 are negative regulators of immune-related signal-
ing pathways. MiR-155 and miR-21 have been shown to regulate
immune tolerance and miR-223 and miR-150 play functional roles
modulating the translation of transcription factors that are essen-
tial for the development of specific immune lineages. Moreover,
their altered expression has been associated with pathological con-
ditions of the immune system, including hematologic cancers and
autoimmunity.
One miRNA that has been determined to play a central role
in immune responses, particularly the innate immune response, is
miR-146a. Its importance was recently confirmed in a miR-146a
knock-out mouse model. In addition to developing autoimmu-
nity, these mice are hyper-responsive to lipopolysaccharide (LPS)
and demonstrate an exaggerated pro-inflammatory response when
challenged with endotoxin. Furthermore, aged knock-out mice
develop tumors in their secondary lymphoid organs and undergo
myeloproliferation, suggesting that miR-146a regulates prolifer-
ation in immune cells (16, 17). Consistent with this latter find-
ing, miR-146a-deficient mice develop myeloid malignancies due
to chronic dysregulation of NF-κB signaling (17). Interestingly,
miR-146a deficient mice develop many of the same abnormal
hematopoietic phenotypes described in a subset of myelodys-
plastic syndrome (MDS) patients with 5q-syndrome in which a
segment of chromosome 5q is deleted. This observation is quite
interesting because miR-146a resides on chromosome 5q33.3 and
because miR-145 and miR-146a expression is reportedly lost in
the CD34+ bone marrow-derived progenitor cells of many MDS
patients with 5q-syndrome (18). In addition, in vitro knockdown
of miR-146a in mouse hematopoietic stem/progenitor cells can
recapitulate many of the phenotypic abnormalities observed in
5q-syndrome. Taken together, these studies suggest a role for miR-
146a as a tumor suppressor and in controlling the proliferation
capabilities of immune cells. This involvement in cell growth and
division likely leads to the high frequency with which alterations
in expression is associated with malignancy.
Similar to miR-155, miR-146a expression is enriched in regula-
tory T (Treg) cells. Knock-out of miR-146a expression in the Treg
cells of mice leads to a fatal breakdown of tolerance and results in
a CD4+ helper T lymphocyte (Th1)-mediated immunopathology
that is dependent on interferon gamma (IFN-γ). Furthermore,
miR-146a’s targeting of the expression of Stat1, a member of the
Signal Transducers and Activators of Transcription family of tran-
scription factors that is involved in upregulating genes in response
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to interferon stimulation, is necessary for the in vivo suppressor
function of Tregs (19). T effector subsets were also deficient for
miR-146a in this model and were shown to produce higher levels
of IFN-γ and to contribute to the pathogenic Th1 response. Fur-
ther work utilizing lineage-specific ablation of conditional alleles
is necessary to clearly define the role of miR-146a in different
lymphocyte subsets.
In this review, we discuss the central role prescribed to miR-
146a in innate immunity. We particularly focus on the role played
by miR-146a in the regulation and signaling mediated by one of
the main PRRs, TLRs. Additionally, we also discuss the role of
miR-146a in several classes of autoimmune pathologies where this
miRNA has been shown to be dysregulated.
TLRs AND miR-146a
Toll/IL-1 receptors are the best studied family of PRRs and were
among the first pathways to be investigated for possible modula-
tion by miRNAs. In human beings, there are 11 TLR homologs
(TLR-1 to TLR-11), each specifically expressed with respect to cell
type, and with unique extracellular or cellular domains that have
the ability to recognize a wide variety of ligands (20). TLRs ini-
tiate the innate immune response by activating several signaling
pathways that depend on adapter molecules, specifically, MyD88
(MyD88 signaling pathway) or the domain-containing adaptor
protein inducing interferon-beta, TRIF, also known as TICAM1
(TRIF signaling pathway). Consequently, these adapter molecules
mediate the downstream activation of the transcription factor
nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB), mitogen activated protein kinases (MAPKs), members
of the interferon regulatory factor family and activator protein-
1 (AP-1), which contribute to the induction of pro-inflammatory
cytokines, type 1 IFNs (IFNs such as IRF3 and IRF7) and anti-viral
proteins (21, 22). The MyD88 pathway, which leads to the activa-
tion of NF-κB and MAPK, is used by most of the TLRs except for
TLR3. TLR3 (and also TLR4) possess the ability to utilize the TRIF
signaling pathway (23, 24).
Sufficient signaling by the TLRs is required for the effective
clearance of pathogens but unrestrained TLR response can also be
deleterious to the host. Therefore, TLR-mediated inflammatory
response must be tightly controlled and the intricate regulatory
potential afforded by miRNAs and miR-146a in particular is, there-
fore, highly pertinent to the physiological operation of this type
of innate immune response. In this section, we discuss three par-
ticular scenarios by which miR-146a is intimately involved in the
control of the mammalian innate immune response mediated by
TLRs. This includes:
(i). The regulation of miR-146a expression by TLR-signaling.
(ii). The direct regulation of TLRs by miR-146a.
(iii). The regulation of TLR-signaling components/molecules by
miR-146a.
THE REGULATION OF miR-146a EXPRESSION BY TLR-SIGNALING
The regulation of miRNA expression by TLR-signaling has been
well documented with a wide assortment of miRNAs exhibiting
altered expression. Nevertheless, a consensus has emerged that
regardless of the TLR-stimulus utilized, the various screening plat-
forms employed, or the cell types used, the induction of two
miRNAs in particular, miR-146a and miR-155, are particularly
prominent suggesting roles in the pathways downstream of TLR
stimulation. The first set of evidence contributing to the role of
miR-146a in innate immunity was acquired from work performed
on the human monocytic THP-1 cell line in response to LPS stimu-
lation or treatment with the pro-inflammatory cytokines, TNF-α,
and interleukin-1 beta (IL-1β) (8). LPS, a TLR4 agonist, was found
to rapidly induce the expression of miR-146a, which was then
shown to act as a negative feed-back regulator of molecules in
the same signaling system used for its own induction in an effort
to dampen the magnitude of the immune response. MiR-146a
has been shown both in vitro and in vivo to directly target two
serine/threonine kinases, interleukin-1 receptor-associated kinase
1 (IRAK1) and tumor necrosis factor (TNF) receptor-associated
factor 6 (TRAF6), that become associated with the interleukin-1
receptor (IL-1R) upon stimulation and are partially responsible
for IL-1-induced upregulation of NF-kB. This binding results in
the suppression of the expression of NF-κB’s target genes such as
the interleukins IL-6, IL-8, IL-1β, and TNF alpha (TNF-α) (8, 16,
25–28) (Figure 2).
The induction of miR-146a by LPS, in response to TLR4-
signaling, is dependent on NF-κB and the miR-146a promoter
contains several putative binding sites (~3) for this transcription
factor (8). Other TLR-agonists that have been shown to induce
miR-146a expression, although to a lesser extent than LPS, include
Pam3CSK4 (TLR2 agonist), peptidoglycan (TLR2 agonist), and
flagellin (TLR5 agonist) (8, 29). Similarly, the infection of murine
macrophages with vesicular stomatitis virus (VSV) induces miR-
146a to negatively regulate the RIG-I anti-viral pathway by target-
ing not only IRAK2 and TRAF6, but also IRAK1, and in doing so
suppressing the production of type-I interferon (i.e., IFNα) (27).
MiR-146a has also been shown to target STAT-1 and IRF-5, both of
which are involved in the type I interferon response pathway (28).
Interestingly, low levels of miR-146a in lupus patients correlate
with higher levels of interferon and with worse clinical manifes-
tation (28). Taken together, the aforementioned studies strongly
depict an extensive role for miR-146a in innate immunity as a
dominant, negative regulator of the pro-inflammatory signaling
cascade.
Studies have also prescribed a role for miR-146a in endotoxin-
induced tolerance (26). Endotoxin tolerance is the hypo-
responsive state of monocytes to subsequent challenge to LPS,
following a period of prolonged LPS exposure. This particular tol-
erance is often necessary to prevent aberrant inflammation due to
continuous exposure to bacterial components, such as those ema-
nating from commensal microflora at epithelial surfaces. Experi-
ments with THP-1 cells have shown that miR-146a levels increase
following LPS exposure (TLR4-signaling) and negatively correlate
with TNF-α levels as the cells develop a state of LPS tolerance (26).
Importantly, tolerance induction requires miR-146a up-regulation
and the transfection of exogenous miR-146a is sufficient to induce
endotoxin tolerance, even in the absence of LPS-priming (26).
Conversely, the knock-down of miR-146a diminishes the effects
of LPS tolerance (29). Subsequent work confirmed these findings
and showed that miR-146a was necessary for LPS-induced cross
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FIGURE 2 | MiR-146a negatively regulates signal transduction pathways
leading to NF-κB activation. Upon activation of a cell surface receptors, such
asTLR4 belonging to theTLR family, a molecular cascade includingTRAF6 and
IRAK1 leads to IκBα phosphorylation and degradation and to NF-κB activation
and nuclear translocation. NF-κB activation induces transcription of many
genes, including pri-miR-146a. Once translocated to the cytoplasm and loaded
onto the RISC complex, mature miR-146a contributes to the attenuation of
receptor signaling through the down-regulation of IRAK1 and TRAF6.
tolerance to several different TLR-ligands (29). Furthermore, miR-
146a is important for innate immune tolerance in the neonatal
intestine because it targets IRAK1 and thereby prevents apoptosis
of intestinal epithelial cells following exposure to bacteria (30). As
a whole, these studies support the key notion that although miR-
146a is induced by TLR-signaling, its key role may be to serve as
a dominant negative feed-back regulator to prevent uncontrolled
inflammation in response to persistent bacterial exposures.
Two additional mechanisms of TLR4/LPS-signaling induced,
miR-146a-mediated, endotoxin tolerance have been reported (31).
Firstly, miR-146a was shown to be involved in the binding of
the transcriptional repressor encoded by the RELB gene to the
promoter region of TNF-α. The binding of RelB (NF-κB mem-
ber) results in the generation of a facultative heterochromatin.
The depletion of miR-146a alone is not sufficient to reverse
the compact nature of the chromatin resulting in the persis-
tence of endotoxin tolerance. It is only when both the RELB
and miR-146a are depleted that the tolerance appears to be
reversed. Secondly, miR-146a has also been shown to regulate the
translational repression of TNFα. This is believed to be medi-
ated through miR-146a preventing the interaction of the RNA-
binding protein effector argonaute-2 (Ago2) and RNA-binding
motif 4 (RBM4), both members of the translational repressor
(miRNA/RISC) complex.
Consistent with the previous themes, the treatment of A549
lung epithelial cells (and also a range of other lung-associated cells
including airway epithelial BEAS2B cells, primary human airway
epithelial cells and primary human airway smooth muscle cells)
with high levels of IL-1β rapidly increases miR-146a and sup-
presses the IL-1β-induced chemokines, IL-8 and RANTES (32,
33). Interestingly, in A549 lung cells, this negative feed-back inhi-
bition was only apparent at high IL-1β concentrations suggesting a
potential role for this miRNA-mediated mechanism during severe
inflammation (32). The induction of miR-146a by IL-1β is medi-
ated by both a mechanism involving NF-κB and also dependent
on a JNK-1/2-mediated mechanism (33). More in depth analysis
of the mechanism of miR-146a induction using pharmacolog-
ical inhibitors revealed that although NF-κB is involved in the
transcription of pri-miR-146a, the MAP kinases, ERK-1/2, and
JNK-1/2 pathways appear to regulate the post-transcriptional pro-
cessing of the mature miR-146a (34). Furthermore, miR-146a is
constitutively expressed at high levels in non-activated Langer-
hans cells (LCs) in the epidermis upon comparison to interstitial
dendritic cells in connective tissues (35). The transcription fac-
tor PU.1 induces miR-146a in response to TGF-β1 signals in
the epidermis, and miR-146a increases the activation threshold
for LCs in response to TLR2-dependent activation. These find-
ings again support a role for miR-146a to negatively regulate
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the innate immune response in epithelial surfaces and suggest
a mechanism for inducing an innate tolerance to commensal
microflora.
Although the molecular mechanism(s) have yet to be fully
elucidated, the induction of miR-146a by TLR7 and TLR9 ago-
nists has now been shown in primary plasmacytoid dendritic cells
(pDCs), where these receptors are clearly expressed (36). pDCs
are one of the main sources of type 1 interferons during micro-
bial infections and TLR7 and TLR9 sense the nucleic acids from
these types of infections. Additionally, activated pDCs also gen-
erate pro-inflammatory cytokines and promote the up-regulation
of co-stimulatory molecules, which in turn promote the prim-
ing of the adaptive immune response mediated by T-, B-, NK-,
and dendritic-cells. The ectopic expression of miR-146a in the
pDC cell line, CAL-1, impaired TLR-mediated signaling through
reduction in the expression of IRAK1 and subsequently NF-κB
activation. Moreover, the enforced expression of miR-146a in these
cells also reduced the viability of the cells and also their role in the
co-stimulation of the adaptive immune response. Interestingly, the
induction of miR-146a by TLR7 and TLR9 activation appears to be
a nature of the cell types used as primary cells (i.e., primary PMBCs
or pDCs) appear to be more conducive for miR-146a induction
than immortalized cell lines (i.e., THP).
Though a clear picture regarding the induction of miR-146a
expression by various TLR-agonists appears to be emerging,
whereby NF-κB appears to be intimately involved at the tran-
scriptional level, less is known about the post-transcriptional stage
and how the mature form of the miRNA is produced. Early evi-
dence with a range of lung-associated cells suggests that MAP
kinases may be involved. Another outstanding question in the field
of miR-146a biology is whether there are TLR-signaling mecha-
nisms that can decrease this and other host miRNA expression
and whether this is related to disease pathobiology. Potentially,
this could be through transcriptional repression and/or through
post-transcriptional mechanisms that may destabilize pri- and
pre-miRNA transcripts. At this conjuncture, however, it would
be premature to dismiss that these topics are not being actively
investigated. Alternatively, TLR-induced miR-146a induction may
also be due to the accelerated processing of pre-miRNA transcripts
and/or even through the delayed degradation of the mature miR-
146a. However, at this time, evidence to support these claims is also
very limited. Moreover, detailed investigations are also required to
delineate the role of other miRNAs that appear to be regulated
by TLR-signaling, alongside miR-146a, including but not limited
to miR-155, miR-21, miR-132, and miR-146b, and also the time
period after stimulation that these miRNAs are induced. Whether
their role is to promote the pathogenesis of the infection, while
miR-146a regulates the magnitude of the immune response, is yet
to be resolved and would certainly provide a more compelling pic-
ture of the role of miRNAs in regulation of the vertebrate innate
immune response. MiR-146b must also be mentioned here as it is
very closely related to miR-146a, differing only by two nucleotides
in its stem-loop region. It is located on a different chromosome
to miR-146a but has an identical seed sequence and thus the same
bioinformatically predicted targets. In fact, it has also been shown
to negative regulate inflammation by interaction with IRAK1 and
TRAF6 mRNAs. In contrast to miR-146a, however, it is expressed
with delayed kinetics in respect to miR-146a in human monocytes
in response to LPS stimulation and it has been shown to be induced
by IL-10 via a STAT3-dependent loop (37). In a very recent study,
miR-146b induction by STAT3 activation was shown to be epige-
netically regulated, its expression being silenced in cancer cell lines
and tumor tissue via methylation (38). In this situation, miR-146b
appears to function as a tumor suppressor, thus highlighting how
context-dependent expression and transcriptional regulation can
provide miRNAs with identical seed sequences and putative targets
with unique biological functions.
THE DIRECT REGULATION OF TLRs BY miR-146a
To activate the immune response, pathogen recognition receptors
(PRRs) must first recognize infecting pathogens. Thus, it might
seem that the first potentially effective point at which to manipu-
late the TLR-signaling pathway is at the level of receptor expression
(22, 39). However, to date, there are not many studies that can
prove that TLRs themselves are directly targeted by miRNAs. It has
been suggested that there are very few highly conserved target sites
in the 3′-UTRs of TLR mRNAs (22). The miRNA target predic-
tion program TargetScan showed that TLR coding genes have very
few highly conserved target sites for miRNAs, and further analy-
sis of the human 3′-UTR TLR region revealed that TLR genes
are targeted by miRNAs mainly through weak, non-conserved
sites (22, 39).
The mRNA encoding TLR4 has been shown to be regulated
by members of the let-7 miRNA family. TLR4 mRNA contains
the let-7e target site, and induction of let-7e expression in mouse
macrophages decreases cell surface expression of this receptor (22,
40). The mRNA encoding TLR4 has also been shown to be tar-
geted by other isoforms of the let-7 family. In human epithelial
cells, TLR4 mRNA is regulated by let-7i (39, 41). Heikham and
Shankar (42) using bioinformatic analysis to predict active miRNA
sites in the 3′UTRs of TLRs showed that myeloid specific miR-
23a was a strong candidate for regulating both TLR4 and TLR 3
expression.
Interestingly, more recently, Yang et al. (43) using a con-
sensus bioinformatics approach, showed a possible interaction
between TLR4 and miR-146a (39). With sustained oxidized low-
density lipoprotein (oxLDL) stimulation, a decrease in expression
of miR-146a appears concomitant with upregulation of TLR4
expression. Conversely, it was also shown that TLR4 can be down-
regulated by over-expression of miR-146a. A luciferase reporter
assay showed that miR-146a was shown to be able to bind directly
to the TLR4 3′UTR target sequence, thus potentially regulating
both oxLDL accumulation and down-regulating TLR4-dependant
intra-cellular signaling pathways (43, 44). For the most part,
these studies do not confirm a direct role for the regulation of
TLR4 expression by miR-146a and, therefore, more detailed work
is required. Although these data suggest that miR-146a has the
potential to regulate at the level of TLR expression in vitro, much
more experimental evidence exists to suggest that its action is most
effective by regulating downstream signaling intermediates such as
IRAK1 and TRAF6, transcription factors and cytokines, to specific
modulation of various parts of the signaling cascade, rather than
a non-specific knock-down of all TLR signaling as would be the
result of regulation at the level of the receptor itself (39).
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THE REGULATION OF TLR-SIGNALING COMPONENTS/MOLECULES BY
miR-146a
In 2006, Taganov et al. (8) published the first report, high-lighting
the vast potential for miRNA regulation of the innate immune
response by analyzing the expression of 200 miRNAs after expo-
sure to THP-1 cells to LPS. Through promoter studies, they
determined that the induction of transcription of miR-146a by
various microbial components and pro-inflammatory mediators
such as LPS, TNFα, and IL-1β is critically dependent on NF-κB
activation (8). IRAK1 and TRAF6 are key adapter molecules in
TLR and IL-1 receptor signaling cascades mediating activation of
NF-κB and AP-1 pathways. These proteins are important compo-
nents of the myeloid differentiation primary response protein 88
(MyD88) dependent pathways for NF-κB activation downstream
of TLR2, TLR4, TLR5, TLR7, TLR8, and TLR9 (8, 22). Multi-
ple target sequence sites for miR-146 were found in the 3′UTRs of
mRNAs encoding IRAK1, and TRAF6. Through luciferase reporter
assays, it was shown that miR-146a can bind to multiple target
sequences within the 3′UTR of IRAK1 and TRAF6 to regulate
their expression. This groundbreaking research implicated miR-
146 to be an important fine-tuner of the immune response by
using negative feed-back regulation of TLR receptor and cytokine
signaling (8). Once induced by NF-κB, miR-146a prevents the pro-
duction of IRAK1 and TRAF6. However, proteins that have already
been synthesized will continue to transduce signals, resulting in
a built-in delay to the action of miR-146a leading to a gradual
down-regulation of the inflammatory signaling cascade (45). Fur-
ther studies have confirmed that miR-146a induction is indeed
NF-κB dependent (17, 45).
In addition to targeting signaling proteins downstream of TLR
receptors, studies have also shown that miR-146a decreases the
expression of chemokines and cytokines, which are normally
pro-inflammatory. These include suppression of CXC-chemokine
ligand 8 (CXCL8) and CC-chemokine ligand 5 (CCL5) in epithe-
lial cells (32), IL-6 and CXCL8 in fibroblasts and TNFα in the
osteoarthritic tissue after IL-1 stimulation (46, 47), TNFα, IL-
1β, and IL-6 by THP1 monocytes during LPS tolerance (26),
type I IFNs by TLR7-stimulated peripheral blood mononuclear
cells (PBMCs) and by Epstein-Barr virus (48, 49), and decreased
expression of type I IFNs, TNFα, IL-1β, and IL-6 in macrophages
during vesicular stomatis virus (VSV) infection or during LPS tol-
erance (22, 27, 39, 44). It is likely that most of these cytokines
and chemokines are negatively regulated by targeted repression of
IRAK1 and TRAF6 (22), and IRAK2 (27).
In 2008, Perry et al. examined miR-146a function by over-
expression and inhibition and showed that IL-1β induced
miR-146a expression negatively regulated the pro-inflammatory
chemokines IL-8 and RANTES in alveolar A549 epithelial cells
(32). To investigate the mechanism by which miR-146a might
negatively regulate IL-8 and RANTES release, they first exam-
ined available databases to predict a number of potential targets.
Not surprisingly, they found that IRAK1 and TRAF6 were promi-
nent targets of miR-146a (30). Interestingly, they found that the
expression and action of miR-146a was observed at a high IL-1β
concentration, which indicated that this negative feed-back mech-
anism is only activated during severe inflammatory response (32).
Further examination of the mechanism of action of miR-146a led
them to believe that this response was unlikely to be mediated
through the down-regulation of IRAK1 and TRAF6, and did not
appear to act upon either IL-8 and RANTES transcription or secre-
tion. Instead, in the case of IL-1β stimulation, they believed that
miR-146a is involved in either direct or indirect targeting of IL-8
and RANTES translation (30, 32).
miR-146a MEDIATED REGULATION OF RIG-1 LIKE AND NOD-LIKE
RECEPTOR SIGNALING
RIG-1-like receptors (RLRs) constitute a family of three cytoplas-
mic RNA helicases that are critical for host anti-viral responses.
They sense double-stranded RNA, a replication intermediate for
RNA viruses, leading to the production of type I IFNs in infected
cells. Many miRNAs can be induced by RIG-1 signaling, and can
control viral replication through regulation of the RIG-I path-
way and the expression of type I interferon (50). In 2009, Hou
et al. first showed that in addition to two known miR-146a tar-
gets IRAK1 and TRAF6, that IRAK2, a kinase that compensates
for IRAK1 to activate NF-κB, was a novel target of miR-146a (27,
39). Using TargetScan to predict new targets of miR-146a, they
found that mouse IRAK2 had three putative miR-146a binding
sites. To examine the possibility that IRAK2 was regulated post-
transcriptionally by miR-146a, they cloned ~1 kb of the 3′UTR
from mouse IRAK2 to the 3′UTR region of firefly luciferase gene
or GFP gene and performed luciferase assays. They showed that
transfection of miR-146a mimics decreased IRAK2 expression in
macrophages at the protein and mRNA levels, whereas miR-146a
inhibitors increased IRAK2 expression, suggesting that IRAK2
expression could be inhibited by miR-146a via both translational
inhibition and mRNA degradation. As such, they reported that
when up-regulated during viral infection, miR-146a is a negative
regulator of the RIG1-dependant anti-viral pathway by target-
ing TRAF6, IRAK1, and IRAK2 (27). This group also further
investigated the effect of miR-146a on VSV-induced production
of pro-inflammatory cytokines and chemokines and found that
miR-146a negatively regulated VSV-induced production of pro-
inflammatory cytokines IL-1β, IL-6, and TNFα and chemokines,
RANTES, in mouse primary macrophages (27).
The nucleotide-binding oligomerization domain (NOD)
leucine-rich repeat-containing receptor (NLR) protein family
coordinates intra-cellular surveillance to mediate innate immune
responses and inflammation (51). There are several NOD leucine-
rich repeat-containing receptor proteins and one of these, NOD2,
acts as an important innate sensor that detects cytosolic PAMPs
as well as DAMPs. NOD2 signaling activation in macrophages
increases the expression of TNF-α, IL-6, cyclooxygenase 2 (COX-
2), and iNOS, an enzyme, which produces nitric oxide that medi-
ates bactericidal actions (52). It was recently reported that NOD2
signaling stimulated by muramyl dipeptide, a component of bac-
terial cell wall, up-regulates the expression miR-146a through
transcription factors, NF-κB, PU.1, HSF2, and Oct-1 in mouse
peritoneal macrophages (53). MiR-146a then directly targets the
NUMB gene leading to its reduced expression and thereby relieves
the suppression of the sonic hedgehog signaling pathway. Activa-
tion of this pathway ultimately leads to the expression of inflam-
matory mediators such as IL-12, TNF-α, IL-6, and the chemokines
CCL-5, and CXCL-9. Although there are few publications to date
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that specifically describe a function for miR-146a in the regulation
RIG-1 like and NOD-like receptor signaling many of its targets,
such as the downstream adaptors IRAK1 and TRAF6, are shared.
The pivotal roles of these targets in signaling pathways downstream
of multiple PRR’s is highly suggestive of an overarching role for
miR-146a in the activation of the innate immune response.
AN EMERGING ROLE FOR miR-146a IN AUTOIMMUNE
DISEASES AND DISORDERS
The emerging role of miR-146a as a dominant negative regula-
tor of the innate immune response has placed great emphasis
on discovering a potential role for the miRNA in the etiology
and/or pathobiology of a wide variety of autoimmune diseases
and disorders. Although many miRNAs have been identified as
being over-expressed and/or under-expressed in these types of
pathologies, miR-146a in particular has been extensively reported
by most investigators. Nevertheless, a harmonious consensus on
the magnitude of miR-146a expression, or the lack thereof, in
autoimmune pathological events has not yet been achieved. Sev-
eral well defined autoimmune diseases and disorders where the
aberrant expression of miR-146a has been identified include sys-
temic lupus erythematosus (SLE), rheumatoid arthritis (RA), and
Sjögren’s syndrome (SjS).
Systemic lupus erythematosus is a complex autoimmune
pathology where tissue and organ damage are caused by the pro-
duction of auto-antibodies, complement activation, and immune-
complex deposition (54, 55). In the PBMCs of SLE patients, the
expression of miR-146a was found to be down-regulated (28). The
down-regulation negatively correlated with the severity of the dis-
ease and also with the interferon response. Elevated IFNα-levels
in the serum of SLE patients is well known, along with the differ-
ential expression of IFN-inducible genes (56–59). Taken together,
this “IFN-signature” has emerged as one of the most significant
contributing factors in the pathobiology of SLE. Remarkably, the
over-expression of miR-146a reduced, while the sequestration of
endogenous miR-146a increased, the induction of type I inter-
ferons in PMBCs. Moreover, the miRNA directly repressed the
trans-activation downstream of type 1 IFNs and can also directly
target for post-transcriptional regulation IFN regulatory factor 5
and STAT-1. More importantly, miR-146a introduction into the
PMBCs of affected individuals alleviated the IFN-signature asso-
ciated with SLE. Genome wide association studies (GWAS) have
also drawn attention to polymorphic regions in the genomic seg-
ments coding for miR-146a and SLE-susceptibility. Within the
Asian population, the variant rs57095329 in the promoter region
of the miR-146a gene, which is suspected of reducing efficient
transcription factor binding (i.e., for Ets-1), contributes to the
decreased expression of the miRNA and an increased risk to
develop SLE (60). Similarly, an increased risk for SLE was identi-
fied in European individuals possessing the variant rs2431697 in
the intergenic region of miR-146a, which reduces the expression of
the miRNA (61). In contrast, screening for SLE-susceptible regions
in the genomic segments around miR-146a did not show any sig-
nificance in an alternate sampling of the Asian population (62).
Taken together, these studies suggest that the under-expression of
miR-146a in SLE may contribute to an aberrant IFN-signature
during the course of the disease.
Rheumatoid arthritis is a phenotypically heterogeneous and
chronically destructive inflammatory pathology of the synovial
joints, often characterized by the presence of auto-antibodies in
afflicted individuals (63). Evidence accumulated so far in the study
of the disease, and specifically through the examination of the role
of the miRNA in the disease, suggests that miR-146a is highly
expressed in patients with RA (25, 64, 65). Increased expression of
miR-146a in RA patients was observed in both the synoviam and
PMBCs, and moreover, correlated with active disease. The hypoth-
esis regarding increased expression of miR-146a and its potential
role in RA stems from the findings that both IRAK1 and NF-κB
are important molecules in octeoclastogenesis through the acti-
vation of osteoclast pre-cursor cells, as well as being direct and
indirect targets of the miRNA, respectively (66, 67). Therefore,
the increased expression of miR-146a and its subsequent down-
regulation of IRAK1 and NF-κB may contribute to the repression
of osteoclastogenesis and contribute to a decrease in joint destruc-
tion. In effect, the increased expression of this miRNA may serve
as a putative biomarker of RA. Additionally, TNFα can also induce
osteoclastogenesis and it has also been shown to lead to the expres-
sion of this miRNA. The over-expressed miR-146a seen here may
be available to suppress osteoclastogenesis induced by TNFα. Link-
ing polymorphisms in miR-146a genomic segments to RA suscep-
tibility has been unsuccessful to date in various ethnic groups
studied, including within the Greek and the Chinese populations
(68, 69). In contrast, a polymorphism in the miR-146a 3′UTR
binding site of IRAK1 has been shown to have some association
with susceptibility to RA (69) and psoriatic arthritis (70).
Sjögren’s syndrome is a chronic autoimmune disease where
focal lymphocyte infiltration and inflammation are observed in
exocrine glands (71). The increased expression of miR-146a has
been observed in PMBCs and salivary glands of both SjS-prone
mice and SjS-patients (71, 72). In theory, the up-regulation of
miR-146a should lead to a concomitant decrease in the expression
of pro-inflammatory cytokines but in SjS-patients, the inverse has
been shown to be true (73–76). This enigmatic finding may be
attributed to some unknown mechanism that disables the ability
of miR-146a to recognize its own set of target genes, leading to
insufficient clearance of antigens and subsequent inflammation.
One potential explanation for this ambiguous mechanism may be
the differing expression patterns of miR-146a target genes IRAK1
and TRAF6 seen in SjS patients (72). With increasing miR-146a
expression in PMBCs of SjS patients, a concomitant decrease in
IRAK1 expression is observed whereas the expression pattern of
TRAF6 increases. Potentially, the lack of a complete concerted
down-regulation of NF-κB upstream molecules, in the presence
of increased miR-146a expression, may account for this unique
inflammatory response in SjS patients.
Taken together, the available evidence does indeed suggest
a strong argument for the role of miR-146a in the pathobiol-
ogy of autoimmune diseases and disorders. Nevertheless, more
work is needed to clarify specific role(s) for the miRNA in the
actual mechanism(s) of pathogenesis. Moreover, it should be
noted that although a genetic component is strongly implicated
in the etiolo-pathobiology of autoimmune diseases and disor-
ders, the role of environmental factors should not be disregarded.
The potential to use circulating miR-146a as diagnostic and/or
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prognostic biomarker of inflammation is a very strong possibil-
ity, as is the modulation of the expression of the miRNA through
over-expression/knock-down approaches as a therapeutic counter
strategy for inflammation induced by autoimmune diseases and
disorders.
AN EMERGING ROLE FOR miR-146a IN NEURODEGENERATIVE
DISORDERS
An intriguing and emerging area of research regarding miR-146a
is its role in the central nervous system (CNS) where it has been
shown to be robustly expressed, and where it may serve a pivotal
role in regulating the unique innate immune response induced in
these tissues in association with neurodegenerative disorders. Sev-
eral studies have identified elevated expression of this miRNA in
the brain and cerebrospinal fluid of patients with Alzheimer’s dis-
ease and age-related macular degeneration (77–79), in the brains
of patients with multiple sclerosis (80), and in primary cultures
of human neuronal and microglial cells stressed with IL-lβ, amy-
loid β, and inducers of oxidative stress (81–83). Additionally, in
prion disease, a uniquely infectious neurodegenerative condition,
up-regulation of miR-146a has been reported in the brains of
human beings and mouse models of the disease (79, 84, 85). The
expression of miR-146a has largely been studied in microglial
cells of the brain, although miR-146a expression has also been
noted in neuronal populations (85, 86). The expression of the
miRNA in microglia cells is consistent with their role as the
primary resident effector cells of the innate immune response in
the brain, with many similarities to macrophages. Their activa-
tion is one of the first pathological features of a neurodegenerative
condition (87). Activated microglia synthesize fairly low levels of
pro-inflammatory cytokines, presumably as an inherent defense
mechanism to prevent the severe pathology that can arise in host
tissue as a result of an acute inflammatory response induced by
rampant signaling in response to neurodegeneration. Neverthe-
less, microglia phenotypic changes are quite evident and are highly
indicative of phagocytic capability.
Although miR-146a functionality has been extensively explored
in macrophages, its role in microglia is just beginning to emerge
and it may well have a pivotal role in keeping the microglial
inflammatory response “in-check” so as not to exacerbate the
neurodegenerative cascade that may ensue with an “un-checked”
mechanism (Figure 3). Interestingly, the levels of miR-146a
have also been shown to increase in aged microglia as well as
macrophages and have been implicated in age-related dysfunction
of macrophages (88, 89). Macrophages from aging mice exhibited
a lack of response to stimulation with LPS and pro-inflammatory
cytokines thus interrupting the negative feed-back regulation loop
regulated by miR-146a. Aberrant NF-κB binding to the miR-146a
promoter was shown to be associated with the abnormal expres-
sion of miR-146a in aged mice. High levels of histone deacetylase
(HDACs) expression were also shown to contribute to the inhi-
bition of miR-146a expression in LPS-stimulated macrophages
FIGURE 3 | A potential role for miR-146a expression in the central
nervous system (CNS) during the course of neurodegeneration. (A)The
increased expression of the miRNA may provide protection from potentially
harmful immune stimulation by regulating the activation of NF-κB. The miRNA
may operate to keep the pro-inflammatory response of microglia “in-check”
and may be beneficial during neurodegeneration. (B) Aberrant expression of
miR-146a may lead to uncontrolled production of neurotoxic inflammatory
factors (IL-1, TNFα, NO, NOO−, H2O2). Nevertheless, to define the exact
sphere of influence of the miRNA, which has the potential to target multiple
gene networks, more in depth studies are required.
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from aged mice in vitro. Furthermore, a number of polymor-
phisms, have been identified that either interrupt its binding site
in the 3′UTR region target genes IRAK1 and TRAF6, or affect the
expression of miR-146a (68–70). These may have an association
with age-related diseases such as RA (as previously mentioned)
as well as Alzheimer’s disease (68, 90). Although metagenomic
studies on miR-146a associated SNPs to date are limited by the
small populations investigated, this is a promising strategy to
determine prognostic and diagnostic markers that are focused on
the non-coding and regulatory segments of the human genome. It
is possible that these dysfunctions may be linked to the increased
risk for disease of aging that have an inflammatory component
such as neurodegenerative diseases and that miR-146a may be a
target for treating such age-related disorders.
In order to fully elucidate the role of miR-146a in microglia
cells and its role in neurodegeneration as a whole, identification
of functionally important miR-146a target genes is warranted.
In general, the inflammatory response to infections involves the
induction of many genes, a process that must be tightly controlled
not only to achieve the effective clearance of the infection but also
to avoid consequences of dysregulated gene expression, such as
uncontrolled inflammation. As only a handful of miRNAs have
so far been linked to the molecular mechanisms of the CNS, and
since neurodegenerative diseases present themselves with an atyp-
ical immune response characterized by the production of both
pro- and anti-inflammatory mediators (91), studies are essential
in understanding the specific component(s) of cellular immune
response or other pathway(s) (i.e., morphological pathways that
accompany activation, chemotaxis, and oxidative-burst) that may
be regulated by miR-146a induction. Considering that no therapy
is currently available for many human neurodegenerative condi-
tions and since miRNAs simultaneously target numerous genes for
silencing, investigations of this type may be beneficial for identi-
fying potential new targets for therapeutic and/or compassionate
intervention.
CONCLUSION
Numerous studies have established a critical role for miR-146a in
inflammation and immunity where it primarily appears to operate
as a dominant negative regulator of the vertebrate innate immune
response. This miRNA appears to “fine-tune” or “dampen” the
innate immune response to possibly prevent an uncontrolled
inflammatory response that may lead to the exacerbation of
the initial infection. MiR-146a mainly operates in this manner
through the targeting for down-regulation NF-κB upstream mol-
ecules IRAK1 and TRAF6, of the MyD88-dependent signaling
pathway, leading to a concerted decrease in the production of
various inflammatory mediators. Despite numerous studies that
show the induction of miR-146a by pro-inflammatory mediators
most notably of the TLR-signaling mechanism, there is still incom-
plete evidence regarding its precise role, mechanism of action, and
the potential landscape of target genes regulated. Also relatively
understudied is whether miR-146a is similarly induced by other
vertebrate PRRs involved in innate immune signaling such as the
signaling mediated by RIG-I-like receptors, AIM2-like receptors
and Nod-like receptors, and also whether miR-146a serves a simi-
lar purpose in these pathways as it does in TLR-signaling. Although
most studies on miR-146a function have been focused on inves-
tigating the TLR pathway and cells involved in inflammation, it
is undoubtedly expressed in numerous other cell types and here
may be involved in a further range of context-specific functions.
Usage of the miR-146a−/− transgenic mouse (16, 17) will aid in
unraveling these, as will investigating the role of this miRNA in the
pathogenesis of human diseases. It will then be an important next
step to determine whether manipulating the levels of expression
of miR-146a, as well as its targets, has therapeutic benefits.
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